• Participants were randomly assigned to receive carboplatin-paclitaxel (control arm) for six cycles with or without intravenous trastuzumab (experimental arm) until progression or unacceptable toxicity. (nih.gov)
  • These two immunotherapies will be administered by intravenous infusions every 2 weeks until disease progression or unacceptable toxicity, for up to 1 year. (medscape.com)
  • Patients are also eligible to cross over to arm II in the presence of unacceptable toxicity. (knowcancer.com)
  • If at any time after stopping study therapy blood tests show disease recurrence, patients restart tyrosine kinase inhibitor and are eligible to cross over to arm I. Patients are also eligible to cross over to arm I in the presence of unacceptable toxicity. (knowcancer.com)
  • Treatment continued until disease progression or unacceptable toxicity. (ascopost.com)
  • All patients were treated until disease progression or unacceptable toxicity, with the primary endpoint being progression free survival (PFS). (pharmacytimes.com)
  • Participants were randomly assigned to receive Welireg (374 patients) or Afinitor (372 patients) until disease progression or unacceptable toxicity. (curetoday.com)
  • In the follow-up, treatment with Keytruda continued for 35 cycles, or approximately two years, or until disease progression or unacceptable toxicity. (curetoday.com)
  • The treatment was continued until the participant withdrew consent, unacceptable levels of toxicity were observed, the study was completed, the investigator decided to terminate the study, or the participant died. (news-medical.net)
  • Patients received a dose every 3 weeks until disease progression or unacceptable toxicity. (cancernetwork.com)
  • Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. (knowcancer.com)
  • The response rate to chemotherapy was 54%, and up to 81% if stable disease cases were included. (dtrf.org)
  • Low dose chemotherapy achieved stable disease and even remission of the lesions with low toxicity. (dtrf.org)
  • THOUSAND OAKS, Calif.--(BUSINESS WIRE)--April 3, 2006--Amgen (Nasdaq:AMGN), the world's largest biotechnology company, today announced pivotal Phase 3 results demonstrating that panitumumab significantly improved progression-free survival and disease control (response rate and stable disease) compared to best supportive care (BSC) in metastatic colorectal cancer patients who had failed standard chemotherapy. (amgen.com)
  • The trial met its primary endpoint, showing superior overall survival (OS) with Opdivo plus Yervoy versus chemotherapy (pemetrexed and cisplatin or carboplatin) in all randomized patients. (pharmiweb.com)
  • In the CheckMate -743 trial, this dual immunotherapy combination demonstrated a clinically meaningful improvement in survival over the standard of care, with 41% of patients who received Opdivo plus Yervoy still alive at two years, compared to only 27% with chemotherapy," said Abderrahim Oukessou, M.D., vice president, thoracic cancers development lead, Bristol Myers Squibb. (pharmiweb.com)
  • Median progression-free survival (PFS) improved from 4.9 months with investigator's choice of chemotherapy to 7.0 months with trastuzumab duocarmazine (SYD985). (medpagetoday.com)
  • One of the most important shifts leading to longer survival of patients with advanced-stage NSCLC was the introduction of increasing lines of chemotherapy. (iiarjournals.org)
  • If possible, people newly diagnosed with AML receive an intensive regimen of multiple chemotherapy drugs, with the goal of pushing the disease into a complete remission -that is, eliminating leukemia cells in the bone marrow . (cancer.gov)
  • This includes patients with muscle-invasive or node-positive disease after receiving neoadjuvant chemotherapy, or those with extravesicular extension or node-positive disease who did not receive neoadjuvant chemotherapy and were ineligible for or refused adjuvant cisplatin-based chemotherapy. (nursingcenter.com)
  • Chemotherapy toxicity rate and profile. (who.int)
  • the benefit of adding adjuvant chemotherapy increases as disease stage increases. (medscape.com)
  • Personalized Medicine in Infant Population with Cancer: Pharmacogenetic Pilot Study of Polymorphisms Related to Toxicity and Response to Chemotherapy. (cdc.gov)
  • Skin toxicities were typically apparent two weeks after beginning treatment. (wikipedia.org)
  • More severe skin toxicities were associated with improved progression free survival and overall survival. (wikipedia.org)
  • More patients in the panitumumab arm reported skin toxicities, fatigue, abdominal pain, nausea and diarrhea. (amgen.com)
  • Pulmonary fibrosis and interstitial lung disease were observed in clinical trials. (wikipedia.org)
  • Interstitial lung disease (ILD): Fatal ILD has occurred in patients receiving irinotecan HCl. (nih.gov)
  • Ocular toxicity is the most prevalent safety event, and ILD [interstitial lung disease]/pneumonitis was reported, including grade 3 or worse, in 2.4% of patients. (medpagetoday.com)
  • In patients with systemic sclerosis-related interstitial lung disease, a clinically meaningful decline of 10% or more in lung function was seen in 24.5% of placebo recipients, compared with 8.6% of tocilizumab recipients. (medscape.com)
  • Notable toxicities included drug-related interstitial lung disease in 24 patients (2 fatalities). (nursingcenter.com)
  • No other associations between single nucleotide polymorphisms and toxicity or survival were found in the treated or untreated group. (arizona.edu)
  • Variations in toxicity and response to therapy are observed among patients despite similar clinicopathologic characteristics which are attributed to single nucleotide polymorphisms (SNPs). (researchsquare.com)
  • So, the aim of this review was to investigate the effect of single nucleotide polymorphisms (SNPs) on response rate and toxicity in HNSCCs. (researchsquare.com)
  • The purpose of the study was to evaluate the toxicity, local control, overall and disease-free survival of elderly breast cancer (BC) patients treated with adjuvant once-weekly ultra-hypofractionated radiotherapy (RT) either with intensity-modulated RT (IMRT) or 3D conformal RT (3DCRT). (nih.gov)
  • Adjuvant treatment with the VEGF receptor tyrosine kinase inhibitors sorafenib or sunitinib showed no survival benefit relative to placebo in a definitive phase III study. (ascopost.com)
  • Although there are clear criteria (pT3-pT4 disease and/or positive margins) for the use of adjuvant radiotherapy, no specific clinical or tumour-related criteria have yet been defined for SRT. (wjgnet.com)
  • one of the four adjuvant studies collected overall survival data. (mendeley.com)
  • Only one adjuvant study collected data on overall survival and disease-free survival but did not report data. (mendeley.com)
  • In a placebo-controlled phase III trial of over 700 patients with urothelial carcinoma (UC) and high-risk disease after radical cystectomy, one year of adjuvant nivolumab improved disease-free survival (median 21 versus 11 months) [1]. (nursingcenter.com)
  • Breast cancer is a heterogeneous disease with a large variabil- survival after adjuvant polychemotherapy was 10% (from ity in clinical outcome. (lu.se)
  • With 18 months of median follow-up, severe early-late toxicity (G3) was reported in terms of fibrosis and breast retraction, both with an incidence of 1.4%, mostly in the 3DCRT group. (nih.gov)
  • Given the patient's extended survival, we present the oncologic rationale for treatment and considerations of late toxicity. (allenpress.com)
  • In a randomized trial among 300 patients with cervical cancer undergoing postoperative radiation, disease-free survival was similar with image-guided IMRT versus 3D-CRT (77 versus 81 percent), but three-year cumulative incidence of late toxicity was reduced (28 versus 49 percent) [3]. (nursingcenter.com)
  • 500 cm 3 was reported as predictive for moderate-severe (≥ G2) acute toxicity. (nih.gov)
  • The aim of this study is to evaluate the dosemetric parameters and acute toxicity of dose-escalated whole pelvis (WP) Intensity Modulated Radiation Therapy (IMRT) and volumetric modulated arc therapy (VMAT) prostate boost following neoadjuvant and concomitant with androgen deprivation therapy in high-risk prostate cancer patients. (scirp.org)
  • The Proctitis and frequency were the commonest acute toxicity and were maximal during the 5th week of radiation therapy. (scirp.org)
  • Odds ratios for grade 3 and 4 hematologic toxicity in the treated group and hazard ratios for DFS associated with selected functional polymorphisms in CYP2B6, CYP3A4, GSTA1, and GSTP1 were estimated by logistic regression and Cox proportional hazard regression. (arizona.edu)
  • The lower risk of developing high-grade hematologic toxicity among women with variant GSTP1 alleles suggests that genetic markers in combination with clinical factors may be useful in defining a subgroup of women who are less susceptible to adverse hematologic toxicities with CP-containing therapies. (arizona.edu)
  • Only 2 had grade 4 toxicity. (dtrf.org)
  • No recorded acute Grade ≥ 3 toxicity. (scirp.org)
  • Acute grade 1 toxicity for Gastrointestinal (GI) and Genitourinary (GU) were 65% and 35% respectively, while Grade 2 toxicity was 30% for both. (scirp.org)
  • There was one grade 2 and one grade 3 toxicity. (oldcitypublishing.com)
  • No grade 4 or 5 toxicities were seen. (oldcitypublishing.com)
  • No patients experienced dose-limiting toxicities, with grade 3 cognitive disturbance and fatigue being resolved with dose interruption. (cancernetwork.com)
  • Belinostat was well tolerated, with grade 3 or 4 toxicities occurring in only 10% of patients. (aacrjournals.org)
  • Treatment was well tolerated with less than 10% grade 3 and 4 toxicities. (cancerindex.org)
  • No grade ≥4 toxicities were observed. (bvsalud.org)
  • The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. (cdc.gov)
  • The long-term results were studied in more detail to evaluate efficacy and toxicity. (lu.se)
  • Eligible patient charts were reviewed to evaluate survival, recurrence patterns and toxicity following reirradiation. (oldcitypublishing.com)
  • The aim of this review was to evaluate the impact of SNPs on toxicity and response to therapy in HNSCCs. (researchsquare.com)
  • An independent, central radiology review board assessed disease progression and tumor shrinkage. (amgen.com)
  • Improvements in progression-free survival and disease control also occurred regardless of age, sex, primary tumor location (colon versus rectum), or performance status. (amgen.com)
  • 2004 ). One problem with cancers, especially HNSCCs, is the unpredictability of treatment outcomes, both in terms of tumor response and host toxicity. (researchsquare.com)
  • Tumor recurrence, disease-free survival (DFS), and side-effects were recorded and compared between the 2 groups. (spandidos-publications.com)
  • In retrospective series, 5-year biochemical progression-free survival (PFS) ranges from 35%-85%, depending on the PSA level at the start of RT. (wjgnet.com)
  • 1990. A review on biochemical roles, toxicity and interactions of zinc, copper and iron: IV. (cdc.gov)
  • Methods Eligible patients had primary stage III or IV or recurrent HER2/neu-positive disease. (nih.gov)
  • The primary end point was progression-free survival, which was assessed for differences between treatment arms via one-sided log-rank tests. (nih.gov)
  • Toxicity and ORR are the primary outcomes. (medscape.com)
  • The primary endpoint was progression-free survival. (ascopost.com)
  • The primary objective was to compare disease-free survival between each experimental group and placebo in the intention-to-treat population. (ascopost.com)
  • The primary analysis showed no significant differences in disease-free survival, with a median duration of 5.8 years (interquartile range [IQR] = 1.6-8.2 years) for sunitinib (hazard ratio [HR] = 1.02, P = .8038, vs placebo), 6.1 years (IQR = 1.7 years to not estimable) for sorafenib (HR = 0.97, P = .7184, vs placebo), and 6.6 years (IQR = 1.5 years to not estimable) for placebo. (ascopost.com)
  • The primary end point was frequency of dose-limiting toxicities in the 21 days following the first infusion of pembrolizumab. (cancernetwork.com)
  • Withhold and then reduce or discontinue STIVARGA depending on severity and persistence of dermatologic toxicity. (nih.gov)
  • Exciting work is being done to identify target-specific therapies to minimize toxicity and improve event-free survival. (medscape.com)
  • Eligible patients had received at least two prior therapies or T-DM1 for metastatic disease. (medpagetoday.com)
  • 6 1 They are highly effective with respect to induction of remission and prolongation of progression-free survival compared to standard therapies in patients with relapsed or refractory disease, high-risk disease (e.g. (haematologica.org)
  • Panitumumab was approved by the U.S. Food and Drug Administration (FDA) for the first time in September 2006, for "the treatment of EGFR-expressing metastatic colorectal cancer with disease progression" despite prior treatment. (wikipedia.org)
  • Toxicity was not different between treatment arms, and no unexpected safety signals emerged. (nih.gov)
  • Determine the toxicity of these treatment regimens in these patients. (knowcancer.com)
  • The multicenter study included 88 patients with an EGFR exon 19 deletion or exon 21 L858R mutation and stage IV NSCLC who were eligible for treatment with bevacizumab and who had received no systemic therapy for stage IV disease. (ascopost.com)
  • After randomization, four patients in the HIPEC arm and six in the control arm were not treated using the intended therapy, one patient because of withdrawal, one because of a life-threatening other malignant disease and the others because of progressive disease before initiation of the treatment. (lu.se)
  • During the follow-up, one patient was crossed over from the control arm and underwent cytoreduction and HIPEC for recurrent disease, after the assigned treatment was completed. (lu.se)
  • Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. (drugs.com)
  • Furthermore, substantial treatment discontinuation occurred because of excessive toxicity, despite dose reductions. (ascopost.com)
  • Panitumumab treatment also showed a clinical benefit in the patients crossing over from the BSC arm, despite their disease progression. (amgen.com)
  • In these patients, panitumumab treatment resulted in a nine percent partial response and 32 percent stable disease, as well as one complete response. (amgen.com)
  • percentage of patients whose disease shrinks or disappears from treatment), safety, and time to deterioration (TTD). (curetoday.com)
  • ONIVYDE is a topoisomerase inhibitor indicated, in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. (nih.gov)
  • TAGRISSO is indicated for the treatment of adult patients with metastatic EGFR T790M mutationpositive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy [see DOSAGE AND ADMINISTRATION ]. (rxlist.com)
  • In addition, patients who received Keytruda for six months or more could also receive a second course with the drug for up to one year after their disease progressed when they stopped their initial treatment. (curetoday.com)
  • Lastly, 21 patients received a second course of Keytruda after their disease progressed following the first round of treatment. (curetoday.com)
  • With the European Commission approval of this dual immunotherapy combination, patients and doctors will now have a new treatment option that has shown significant improvements in survival to manage this resistant disease. (pharmiweb.com)
  • The rationale for proton beam therapy was that a local treatment could be provided while delivering less radiation to adjacent lungs, thereby decreasing the risk of acute and late radiotherapeutic toxicities. (allenpress.com)
  • By examining the SNPs, it is possible to make predictions about the patient's response to treatment or development of toxicity after treatment, and if necessary, make changes in the patient's treatment regimen. (researchsquare.com)
  • On the other hands, researches have been conducted to find molecular markers for predicting the development of treatment-induced acute or chronic toxicity before initiation of treatment (Venkatesh et al. (researchsquare.com)
  • Ocular toxicity was the most common treatment-emergent adverse event (TEAE) with SYD985 and was associated with a discontinuation rate of 20.8%, reported Cristina Saura Manich, MD, PhD, of Vall d'Hebron University Hospital in Barcelona, during the virtual European Society for Medical Oncology (ESMO) meeting. (medpagetoday.com)
  • Treatment with SYD985 significantly improved progression-free survival in comparison with standard physician's choice treatment in patients with HER2-positive metastatic breast cancer with two prior regimens or T-DM1 (trastuzumab emtansine, Kadcyla) in the metastatic setting," she said in conclusion. (medpagetoday.com)
  • The treatment was administered up to disease progression. (iiarjournals.org)
  • In the event of treatment-related toxicity, dose reduction or interruption was permitted. (iiarjournals.org)
  • The combination treatment of fecal microbiota transplantation with tislelizumab and fruquintinib was found to be manageably safe and resulted in improved survival in patients with microsatellite stable metastatic colorectal cancer. (news-medical.net)
  • The trial planned for people to receive at least six monthly rounds of treatment, but participants could continue therapy as long as their disease remained under control. (cancer.gov)
  • Secondary outcomes included disease-free survival, pathological response (in the neoadjuvant setting only), adverse events, treatment adherence and quality of life. (mendeley.com)
  • Disease-modifying treatment aims at inhibiting tissue fibrosis and vascular and immune system alterations, which are the three crucial components of disease pathogenesis. (medscape.com)
  • In a phase III trial of almost 500 patients with unresectable or metastatic treatment-refractory GIST, the tyrosine kinase inhibitor (TKI) avapritinib resulted in similar progression-free survival (PFS) compared with the antiangiogenesis agent, regorafenib [4]. (nursingcenter.com)
  • The Journal of Alzheimer's Disease is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer's disease. (iospress.com)
  • Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer. (cdc.gov)
  • 1998. Zinc acetate treatment in Wilson's disease. (cdc.gov)
  • Ocular toxicity or keratitis was observed in 16% of patients on panitumumab, usually necessitating the discontinuance of therapy. (wikipedia.org)
  • Rates of severe toxicity were reduced with the IMRT technique. (nih.gov)
  • Dose escalation in two phases utilizing Simultaneous integrated boost (SIB) combined with ADT in high risk prostate cancer patient is feasible and associated with acceptable acute GI and GU toxicity. (scirp.org)
  • Two dose-limiting toxicities occurred in the trial at a daily dose of 800 mg. (cancernetwork.com)
  • These] limited data suggest that the combination of tisagenlecleucel and pembrolizumab was feasible and showed a manageable safety profile, with no dose-limiting toxicities or significant exacerbation of tisagenlecleucel-related AEs,' according to the authors of the phase 1b PORTIA study (NCT03630159). (cancernetwork.com)
  • No AE-related discontinuations or dose-limiting toxicities were reported. (cancernetwork.com)
  • These] limited data suggest that the combination of tisagenlecleucel and pembrolizumab was feasible and showed a manageable safety profile, with no dose-limiting toxicities or significant exacerbation of tisagenlecleucel-related AEs. (cancernetwork.com)
  • In clinical trials, 90% of patients had dermatological toxicities and 15% of those were severe. (wikipedia.org)
  • Mesothelioma can be a devastating diagnosis for patients and their families, and the disease has a significant impact throughout Europe, which has the highest incidence rate of mesothelioma globally," said Stefania Vallone, board member, Women Against Lung Cancer in Europe. (pharmiweb.com)
  • Hispanic children also have an increased incidence of high-risk disease when compared with whites, but less so than African Americans. (medscape.com)
  • The study population had a median age of about 57, a median duration of metastatic disease of 3 to 3.5 years, and a median of four to five prior metastatic regimens. (medpagetoday.com)
  • In a phase II trial reported in JAMA Oncology , Thomas E. Stinchcombe, MD , and colleagues found that the addition of bevacizumab to erlotinib did not significantly improve progression-free survival (PFS) in patients with advanced EGFR- mutant non-small cell lung cancer (NSCLC). (ascopost.com)
  • The addition of bevacizumab to erlotinib did not significantly improve progression-free survival. (ascopost.com)
  • Conclusion: With 90% of all events having taken place up to this time, this randomized trial shows that cytoreduction followed by HIPEC does significantly add survival time to patients affected by peritoneal carcinomatosis of colorectal origin. (lu.se)
  • A significantly higher proportion of patients were alive and free of disease progression on panitumumab at all of the scheduled time points through week 32. (amgen.com)
  • 1 , 2 , 4 - 6 Specifically, patients with lactate dehydrogenase ≥2 times the upper limit of normal (ULN) at diagnosis, R/R disease within 6 months of diagnosis, multisite relapse, and/or R/R disease with bone marrow involvement experience a significantly decreased OS ( Table 1 ). (jnccn.org)
  • Results: Progression-free survival was not significantly different between patients with KRAS mutation and those with wild-type KRAS. (iiarjournals.org)
  • Compare clinical response, in terms of 1-year progression-free survival and rate of molecular complete remission, in patients with Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) in chronic phase who have achieved a complete cytogenetic remission to single-agent tyrosine kinase inhibitor treated with interferon alfa and sargramostim (GM-CSF) vs tyrosine kinase inhibitor and GM-K562 cell vaccine. (knowcancer.com)
  • If at any time after stopping study therapy blood tests show disease recurrence, patients restart tyrosine kinase inhibitor and are eligible to cross over to arm II. (knowcancer.com)
  • BCR-ABL-negative disease confirmed by 2 PCR assays separated by 1 month) at the end of the 6-month period, discontinue study therapy and are monitored for disease recurrence by blood tests every 4 weeks. (knowcancer.com)
  • Patients who achieve BCR-ABL-negative disease during the additional 6 months of therapy, discontinue study therapy and are monitored for disease recurrence by blood tests every 4 weeks. (knowcancer.com)
  • Patients with BCR-ABL-negative disease at the end of the 6-month period discontinue study therapy and are monitored for disease recurrence by blood tests every 4 weeks. (knowcancer.com)
  • PSMA PET/CT detected disease in 46.9% of patients, compared with 15.5% using diagnostic CT (PSMA PET, 29.2% local recurrence and 29.6% pelvic nodal disease). (snmjournals.org)
  • Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, 4770 Buford Highway, N.E. (cdc.gov)
  • Oncological outcomes at a median follow-up of 2.9 years reported 249/271 (91.9%) patients alive and free from any event and 5 (1.8%) isolated locoregional recurrences. (nih.gov)
  • Each participant will take a belzutifan tablet and lenvatinib capsule daily until disease progression or discontinuation and receive intravenous pembrolizumab once every 6 weeks for up to 2 years. (medscape.com)
  • Patients with a nega- greater risk of hepatic toxicity following intravenous (IV) drug users [14-16]. (who.int)
  • Forty progression-free survival-related events occurred among 58 evaluable participants. (nih.gov)
  • Conclusion Addition of trastuzumab to carboplatin-paclitaxel was well tolerated and increased progression-free survival. (nih.gov)
  • Median progression-free survival was 17.9 months in the combination group vs 13.5 months in the erlotinib group (hazard ratio [HR] = 0.81, P = .39). (ascopost.com)
  • The investigators concluded, "Erlotinib plus bevacizumab compared with erlotinib did not result in a significant improvement in [progression-free survival] in EGFR -mutant NSCLC. (ascopost.com)
  • Progression-free and disease-specific survival were analyzed using the Kaplan Meyer test and compared using the log rank method. (lu.se)
  • The median progression-free survival was 7.7 months in the control arm and 12.6 months in the HIPEC arm (P = 0.020). (lu.se)
  • For example, after six months (week 24) approximately four times as many panitumumab-treated patients were alive and progression-free (18 percent versus five percent with BSC alone). (amgen.com)
  • Twice as many panitumumab-treated patients were alive and progression-free at week 32 (10 percent versus four percent with BSC alone). (amgen.com)
  • Panitumumab improved progression-free survival and response rate regardless of the measured level or intensity of EGFr staining. (amgen.com)
  • In a Phase III trial, The Radiation Therapy Oncology Group (RTOG) showed improved progression-free survival (PFS) for high-risk prostate cancer patients treated with Whole Pelvis Radiation Therapy (WPRT) compared with prostate-only radiation therapy (PORT) [4]. (scirp.org)
  • Median progression-free survival rates were also superior for those with a PD-L1 TPS of 50% or greater (5.3 months versus 4.2 months) and 1% or greater (4 months versus 4.1 months). (curetoday.com)
  • The use of novel B-cell receptor signaling inhibitors results in high response rates and long progression-free survival in patients with indolent B-cell malignancies, such as chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinemia. (haematologica.org)
  • However, among 13 patients whose tumors harbored a platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation, avapritinib improved progression-free survival (median not reached versus 4.5 months). (nursingcenter.com)
  • citation needed] Panitumumab was initially approved on September 27, 2006, for EGFR-expressing, metastatic CRC with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing regimens, based on the results of a study which showed clinical benefit in metastatic colorectal cancer patients. (wikipedia.org)
  • In general, mediastinal soft tissue sarcomas have a poor prognosis with a mean survival ranging from 4 to 34 months [ 2 , 5 - 9 ]. (allenpress.com)
  • Patients with unresectable hepatocellular carcinoma (HCC) have a poor prognosis due to advanced stage of disease and frequent concomitant chronic liver disease. (aacrjournals.org)
  • however, the strength of the recommendation to treat should be based on the patient's willingness to accept therapy as well as the prognosis for AIDS-free survival as determined by the HIV RNA copy per mL of plasma and the CD4+ T cell count. (cdc.gov)
  • Panitumumab reduced the rate of disease progression by approximately half compared to best supportive care alone in these heavily pre-treated patients," said Marc Peeters, M.D., Ph.D., coordinator of Digestive Oncology Unit, University Hospital Ghent, and one of the study's lead investigators. (amgen.com)
  • Furthermore, the difference in objective response rates and the proportion of patients with disease stabilization between panitumumab and best supportive care alone demonstrated the significant activity of this agent. (amgen.com)
  • The stable disease rate was 28 percent with panitumumab versus 10 percent with BSC alone. (amgen.com)
  • Approximately 75 percent of the best supportive care patients entered a cross-over arm to receive panitumumab after their disease had progressed (n=174). (amgen.com)
  • In a phase II trial of the hypoxia-inducible factor-2alpha inhibitor belzutifan in 61 patients with VHL disease, objective response rates were 49 percent in systemic therapy-naive renal cell carcinoma (RCC), 30 percent in central nervous system (CNS) hemangioblastomas, and 91 percent in pancreatic neuroendocrine tumors (pNET) [6,7]. (nursingcenter.com)
  • A web-based search of all original articles about the impact of gene polymorphisms on toxicity and response to therapy in HNSCCs was done until September 2021 using international English language databases including Google Scholar, Scopus, PubMed and Web of science. (researchsquare.com)
  • One patient (2.4%) experienced a partial response, 19 patients (45.2%) had stable disease, and 22 patients' (52.4%) disease progressed. (aacrjournals.org)
  • Patients who cannot undergo complete resection or have an unresectable disease have poor prognoses [ 2 ]. (allenpress.com)
  • The median disease-specific survival was 12.6 months in the control arm and 22.2 months in the HIPEC arm (P = 0.028). (lu.se)
  • Following reirradiation with SBRT, four patients (33%) are alive and disease free. (oldcitypublishing.com)
  • Individuals with another concomitant cancer, autoimmune disease, a history of immunotherapy or organ transplantation, any factors that would impact the absorption of oral drugs, and those prescribed systemic immunosuppressive therapy were excluded from the study. (news-medical.net)
  • To date, the US Food and Drug Administration (FDA) has approved nintedanib and as well as tocilizumab for refractory, progressive intersitial lung disease due to systemic sclerosis. (medscape.com)
  • CRS-related organ toxicities affected 2 patients, and 4 patients required systemic anticytokine therapy. (cancernetwork.com)
  • Systemic toxicity can result from skin or eye exposures. (cdc.gov)
  • These drugs inhibit Bruton tyrosine kinase (BTK) or phosphatidylinositol 3-kinase (PI3K), key components of the B-cell receptor signaling pathway that is crucial for proliferation, survival and homing of malignant B cells. (haematologica.org)
  • 14 Inhibition of BTK in malignant B cells induces diminished proliferation, decreased survival and impaired adhesion and migration of the malignant B cells to their growth-promoting microenvironment. (haematologica.org)
  • These drugs are especially being used for previously unmet needs, i.e., for patients with relapsed or refractory disease, high-risk cytogenetic or molecular abnormalities, or with comorbidities. (haematologica.org)
  • BCR-ABL-positive disease) after completion of the initial 6 months of therapy, receive an additional 6 months of therapy as above. (knowcancer.com)
  • Patients with BCR-ABL-positive disease after the completion of the initial 6 months of therapy, receive an additional 6 months of therapy as above. (knowcancer.com)
  • With a median follow-up of 16.9 months, 99 patients have died, yet survival data are immature with ongoing follow-up occurring. (pharmacytimes.com)
  • Acute radiation toxicities were reported during the radiation course and the following 3 months. (scirp.org)
  • Local control was 92% with a median survival of 24 months (95% CI: 8-38 months). (oldcitypublishing.com)
  • For around 6% to 10% of people with AML , the disease is driven by changes in a gene called IDH1 . (cancer.gov)